Cargando…

Recognition and Treatment of BCG Failure in Bladder Cancer

Patients with high-grade Ta, T1, or carcinoma in situ non–muscle-invasive bladder cancer (NMIBC) are at high risk for recurrence and, more importantly, progression. Thus, both the American Urological Association and European Association of Urology recommend initial intravesical treatment with bacill...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lightfoot, Andrew J., Rosevear, Henry M., O'Donnell, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2011
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720015/ https://www.ncbi.nlm.nih.gov/pubmed/21399857 http://dx.doi.org/10.1100/tsw.2011.30

Ejemplares similares

Treatment options in non-muscle-invasive bladder cancer after BCG failure
por: Brooks, Nathan A., et al.
Publicado: (2015)

Bladder Cancer Immunotherapy: BCG and Beyond
por: Askeland, Eric J., et al.
Publicado: (2012)

Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2016)

Rubin H. Flocks and Colloidal Gold Treatments for Prostate Cancer
por: Rosevear, Henry M., et al.
Publicado: (2011)

Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer
por: Kamat, Ashish M., et al.
Publicado: (2017)

BCG in Bladder Cancer Immunotherapy
por: Jiang, Song, et al.
Publicado: (2022)

Intravesical Treatments of Bladder Cancer: Review
por: Shen, Zancong, et al.
Publicado: (2008)

Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
por: Lukacs, S., et al.
Publicado: (2013)

Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins
por: Saban, Marcia R, et al.
Publicado: (2007)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-α
por: Saban, Marcia R, et al.
Publicado: (2008)

Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment
por: To, Uyen, et al.
Publicado: (2014)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)

The use of intravesical BCG in urothelial carcinoma of the bladder
por: Alhunaidi, Omar, et al.
Publicado: (2019)

Haemophagocytic lymphohistiocytosis after intravesical BCG administration for bladder cancer presenting with multiorgan failure
por: Liatsos, G. D., et al.
Publicado: (2023)

Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study
por: Pichler, Renate, et al.
Publicado: (2021)

Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Li, Roger, et al.
Publicado: (2017)

Autophagy Controls BCG-Induced Trained Immunity and the Response to Intravesical BCG Therapy for Bladder Cancer
por: Buffen, Kathrin, et al.
Publicado: (2014)

Systemic BCG‐osis following intravesical BCG instillation for bladder carcinoma
por: Liaw, Frank, et al.
Publicado: (2017)

Evaluating the neonatal BCG vaccination programme in Ireland
por: Usher, Cara, et al.
Publicado: (2016)

Role of urothelial cells in BCG immunotherapy for superficial bladder cancer
por: Bevers, R F M, et al.
Publicado: (2004)

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
por: Lim, Chun Jye, et al.
Publicado: (2021)

Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer
por: Luo, Yi, et al.
Publicado: (2011)

Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studies
por: Kiselyov, Alex, et al.
Publicado: (2015)

BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets
por: Claps, Francesco, et al.
Publicado: (2023)

Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG
Publicado: (2015)

Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer
por: Saad, Farouk Tijjani, et al.
Publicado: (2017)

Nano-BCG: A Promising Delivery System for Treatment of Human Bladder Cancer
por: Buss, Julieti Huch, et al.
Publicado: (2018)

Mathematical modeling of BCG-based bladder cancer treatment using socio-demographics
por: Savchenko, Elizaveta, et al.
Publicado: (2023)

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Curcumin as Treatment for Bladder Cancer: A Preclinical Study of Cyclodextrin-Curcumin Complex and BCG as Intravesical Treatment in an Orthotopic Bladder Cancer Rat Model
por: Falke, J., et al.
Publicado: (2018)

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer
por: Mackel, Charles E, et al.
Publicado: (2016)

Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer
por: Seegobin, Karan, et al.
Publicado: (2017)

Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021)

BCG Induced Necrosis of the Entire Bladder Urothelium
por: Krönig, Malte, et al.
Publicado: (2015)

Role of Intravesical BCG as a Therapeutic Vaccine for Treatment of Bladder Carcinoma
por: Doroud, Delaram, et al.
Publicado: (2022)

The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer
por: Correa, Andres F., et al.
Publicado: (2015)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
por: Bhat, Suresh, et al.
Publicado: (2015)

BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis
por: Schwarzer, Katja, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_4q287gvp7q3q322ga5ehge6985